Author Archives: Patricia Silva PhD

Mediaplanet, a content marketing company, recently launched a “Personal Health” campaign that helps to raise awareness of different forms of lung disease, from pulmonary fibrosis and cancer to asthma and chronic obstructive pulmonary disease. According to a press release, the campaign — which covers other chronic diseases…

A Rare Conditions Care Value (RCCV) program providing access to “second opinions” for patients with rare diseases like idiopathic pulmonary fibrosis (IPF) was recently launched by two U.S. health management companies, Express Scripts and Pinnacle Care. Second Opinion, as the service is called, offers precisely that— another opinion…

Supported by an educational research grant from Genentech, the France Foundation is launching a mentoring and relationship-building program for community healthcare providers to improve how patients with idiopathic pulmonary fibrosis (IPF) are diagnosed and treated. The program aims to bring front-line health practitioners into closer and long-term contact with…

The Pulmonary Fibrosis Foundation (PFF) has added 15 treatment sites to its nationwide Care Center Network (CCN) — including one each in Wisconsin and Iowa, states which previously did not have centers with recognized expertise in diagnosing and treating pulmonary fibrosis patients. “As the leading resource for the pulmonary fibrosis…

The digital healthcare company patientMpower recently released a new platform called patientMpower for Lung Transplant for patients with pulmonary fibrosis (PF) and other conditions who have received a lung transplant. In January, patientMpower was one of three winners of the $1 million IPF Catalyst Challenge, an award given to projects focused on…

BerGenBio’s bemcentinib (BGB324) stops the progression of aggressive tissue scarring in the lungs and liver, preclinical-trial research shows. Researchers published the findings in the American Journal of Respiratory and Critical Care Medicine. The article is titled “Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.” The results were also presented…

The U.S. Food and Drug Administration recently granted orphan drug status to Reviva Pharmaceuticals’ treatment candidate RP5063 for idiopathic pulmonary fibrosis (IPF). Reviva is now planning to launch Phase 2 studies testing RP5063 in both IPF and pulmonary arterial hypertension (PAH) patients. The FDA granted orphan…

Boehringer Ingelheim’s signature Breathless Campaign will collaborate with Minor League Baseball this season to raise awareness of idiopathic pulmonary fibrosis (IPF). The baseball league has named Boehringer Ingelheim an official IPF awareness partner. In this role, the company will work to educate the league’s fan base about IPF,…

The Pulmonary Fibrosis Foundation’s annual Broadway Belts for PFF! fund-raiser generated a record $350,000 this year. This brought the amount raised in the event’s eight years to nearly $1.2 million. The proceeds support the foundation’s work and research seeking a cure for pulmonary fibrosis. Julie Halston, a Broadway star and comedienne,…

HGE Health of Philadelphia is partnering with the Temple Lung Center to offer a telemedicine disease management program for idiopathic pulmonary fibrosis (IPF) patients in the United States and elsewhere. The healthcare technology company already has a similar program for patients with chronic obstructive pulmonary disease, or COPD. The Temple Lung Center, part…